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Abstract
 
The well defined, immature murine dendritic cell (DC) line D1 was used to study the role of
DC maturation in CTL induction in vitro and in vivo. Maturation of D1 cells, characterized by
markedly increased expression of MHC and costimulatory molecules, was induced by incuba-
tion with lipopolysaccharide, agonistic CD40 antibody, or specific CD4
 
1
 
 T helper (Th) cells.
Activated, but not immature, D1 cells efficiently primed alloreactive T cell responses in vitro.
Similarly, priming of CTL immunity in vivo in CD4-depleted mice was only observed if these
mice were immunized with activated D1 cells. This study provides formal evidence that activa-
tion of DCs, induced by Th-independent as well as Th-dependent stimuli, is essential for effi-
cient induction of CTL responses.
Key words: dendritic cells • CD40 ligation • lipopolysaccharide • Th cells • cytotoxic T 
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Introduction
 
Dendritic cells (DCs) comprise a family of professional
APCs that are present in low numbers in many body tissues
(1). DCs are crucial for the initiation of primary immune
responses of both helper and cytotoxic T lymphocytes, and
thus act as “nature’s adjuvant”. DCs can differentiate from
immature to mature stages. Maturation of DCs is character-
ized by a decreased antigen processing capacity and an in-
creased cell surface expression of MHC and costimulatory
molecules (1–3). In addition, rearrangement of cytoskele-
ton (4), adhesion molecules (5), and cytokine receptors (6)
upon maturation allows DCs to migrate to lymphoid or-
gans, where they can induce primary T cell responses.
An important cognate event in the development of cell-
mediated immunity is the interaction between CD40 and
CD40 ligand (CD40L). CD40 is fairly widely distributed
and is expressed on B lymphocytes, monocytes, and DCs,
but also on endothelial and epithelial cells (7). The ligand of
CD40 (CD40L or CD154) has a more restricted distribu-
tion, being mainly expressed by activated CD4
 
1
 
 T lympho-
cytes (8). In vivo, use of CD40-stimulatory antibodies has
shown that CD40 signaling provides help for the induction
of CTL responses (9, 10). The CD40-specific antibody
FGK45 was capable of replacing T cell help in CD4-depleted
mice for cross-priming adenovirus- and OVA-specific CTLs
(9, 10). The fact that the role of B cells was excluded im-
plied the involvement of DCs. Still, activation and func-
tional antigen presentation by DCs was not formally proven
in these in vivo experiments. In related studies, DC popula-
tions were used for activation by CD40 antibodies in vitro
and tested for their CTL priming capacity in vitro and in
vivo (11). However, these DCs were not phenotypically
immature, as indicated by their very high expression levels
of B7.2. No studies have been reported in which highly pu-
rified immature and mature DC preparations have been
compared with respect to their CTL-inducing capacity in
vitro and/or in vivo. It is indeed very difficult, if not impos-
sible, to obtain such pure populations. We have therefore
used the well characterized growth factor–dependent, long
term DC line D1 to examine the role of activation of DCs
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by different stimuli in the induction of T cell responses.
This nontransformed homogeneous DC population is of
C57BL/6 origin and is spleen derived (4, 12). Immature D1
cells are characterized by proliferative capacity, high antigen
uptake ability, and low T cell–stimulatory efficiency, thus
behaving as “classical” immature DCs. Moreover, expres-
sion levels of costimulatory molecules and cell surface MHC
class I molecules are low, whereas cell surface MHC class II
expression is intermediate. Upon activation by living bacte-
ria or the bacterial component LPS, D1 cells can be acti-
vated to full maturation. This results in cell growth arrest,
low antigen uptake, and high expression of costimulatory
and MHC molecules at the cell surface (12).
Although the concept of requirement of DC maturation
for CTL induction is well established, no formal evidence
bearing out this concept has been published thus far. Here
we report that functional maturation of DCs is essential for
effective CTL priming capacity in vitro and in vivo. In the
absence of CD4
 
1
 
 T cells, this can be achieved indepen-
dently by either of two signals: CD40 triggering or LPS
stimulation.
 
Materials and Methods
 
Mice. 
 
Female C57BL/6 (B6; H-2
 
b
 
) and BALB/c (H-2
 
d
 
)
mice were obtained from IFFA Credo, and BALB/c 
 
3
 
 C57BL/6
F1 (CB6 F1, H-2
 
dxb
 
) mice were from Charles River Laboratories.
Mice were maintained under specific pathogen–free conditions
and used at 6–10 wk of age.
 
Cell Lines and Reagents. 
 
Adenovirus type 5 E1–transformed
B6 mouse embryo cells (Ad5E1-MECs) were generated as de-
scribed (10). P815 is a DBA/2 (H-2
 
d
 
)-derived mastocytoma cell
line. Cell lines were cultured in IMDM (BioWhittaker) contain-
ing 8% heat-inactivated FCS (Greiner), 100 IU/ml penicillin, 2
mM 
 
l
 
-glutamine, and 20 
 
m
 
M 2-ME. Th1 cells were obtained
from DO11.10 TCR-transgenic mice (13) on BALB/c back-
ground (H-2
 
d
 
). These Th cells can efficiently recognize OVA
helper peptide as presented in I-A
 
b
 
. LPS of 
 
Escherichia coli 
 
(sero-
type 0111:B4) was from Difco Labs. The FGK45 hybridoma (14)
was provided by Dr. A. Rolink (Basel Institute for Immunology,
Basel, Switzerland) and used as concentrated hybridoma super-
natant with endotoxin levels below detection (Limulus Amebo-
cyte Lysate COATEST
 
®
 
 for endotoxin). Synthetic peptides
used were: E7
 
CTL
 
 (HPV16 E7 49–57), RAHYNIVTF; E1A
 
CTL
 
(E1A 234–243), SGPSNTPPEI; and OVA
 
Th
 
 (OVA 323–339),
ISQAVHAAHAEINEAGR.
 
DCs. 
 
D1 cell line, a long term growth factor–dependent
immature splenic DC line derived from B6 (H-2
 
b
 
) mice, was cul-
tured as described (4). Both floating and adherent cells (detached
using 2 mM EDTA) were collected and used.
 
Antibodies and Cell Surface Immunofluorescence. 
 
The following
antibodies were purchased from PharMingen: FITC-coupled
CD86/B7.2 antibody (GL1), FITC-coupled CD8 antibody
(Ly2), and PE-conjugated anti–class II (I-A
 
b,d
 
/E
 
d
 
) antibody
(2G9). PE-coupled CD40 antibody (3/23) was obtained from Se-
rotec. Anti–class I (K
 
b
 
) mAb (B8-24-3) was purified and biotiny-
lated. D1 cells were incubated with antibodies in the presence of
30% 2.4G2 supernatant (rat anti–mouse Fc
 
g
 
RIII/II) to block
FcR binding. PE-conjugated, E1A
 
CTL
 
-loaded H-2D
 
b
 
 tetramers
were provided by T. Schumacher (Netherlands Cancer Institute,
Amsterdam, The Netherlands). Staining for tetramer complexes
was carried out as described (15). Flow cytometry was performed
with FACScan™ (Becton Dickinson).
 
Induction of Allospecific Responses In Vitro. 
 
Immature D1 cells
or D1 cells that were treated with 10 
 
m
 
g/ml LPS or 30 
 
m
 
g/ml
FGK45 for 48 h were irradiated and incubated at graded doses
with allogeneic BALB/c spleen cells in 96-well flat-bottomed
plates. Syngeneic B6 spleen cells were used as control. Allospe-
cific proliferation was measured after 4 d. 18 h before termina-
tion, 0.5 
 
m
 
Ci [
 
3
 
H]thymidine was added per well. To induce al-
lospecific CTLs, 3 
 
3
 
 10
 
6
 
 BALB/c spleen cells were incubated
with 10
 
4
 
 irradiated immature D1 cells or LPS- or FGK45-treated
D1 cells in 24-well plates. After 6-d incubation at 37
 
8
 
C, cells
were harvested and used as effectors in a cytotoxicity assay. 
 
51
 
Cr-
labeled cells of H-2
 
b
 
 haplotype (RMA) or H-2
 
d
 
 haplotype (P815)
were used as targets. Percent specific lysis of triplicate wells was
calculated (10).
 
Induction of CTL Responses In Vivo. 
 
To induce CTL responses
in vivo, untreated D1 cells or D1 cells treated for 48 h with 10
 
m
 
g/ml LPS, 30 
 
m
 
g/ml FGK45, or Th1 cells (DC/Th
 
 5 
 
10:1,
in the presence of 5 
 
m
 
M OVA
 
Th
 
 peptide) were loaded with
E1A
 
CTL
 
 peptide for 2 h at 37
 
8
 
C and washed five times. 10
 
6
 
 D1
cells were injected intravenously into B6 mice (LPS- and
FGK45-treated D1 cells) or CB6 F1 mice (Th1-treated D1 cells)
in PBS with 0.5% BSA. CB6 F1 mice were used to avoid allore-
sponses (Th1 cells are BALB/c derived). Mice were depleted of
CD4
 
1
 
 cells by intraperitoneal injection of 100 
 
m
 
g of purified
CD4 antibody GK1.5 in PBS at day 5, 3, and 1 before and at day
1 and 7 after injection of D1 cells. Depletion was performed to
prevent endogenous CD4
 
1
 
 Th cells from activating the D1 cells
in vivo (our unpublished results). After 10 d, spleen cells (5 
 
3 
 
10
 
6
 
per well) were restimulated with irradiated Ad5E1-MECs (5 
 
3
 
10
 
5
 
 per well) in 2-ml cultures in 24-well plates in the absence of
additional cytokines. After 6 d, lymphocyte cultures were tested
for cytotoxicity against Eu
 
3
 
1
 
-labeled RMA cells loaded with
E1A
 
CTL
 
 peptide or control E7
 
CTL
 
 peptide.
 
IL-12 Production. 
 
D1 cells (10
 
6
 
) were seeded in 24-well plates
with OVA
 
Th
 
-specific Th1 cells (D1/Th
 
 5 
 
10:1) in the presence
or absence of 5 
 
m
 
M OVA
 
Th
 
 peptide. After 48-h culture at 37
 
8
 
C,
supernatants were tested for IL-12 p40 content using a standard
sandwich ELISA. Coating antibody was rat anti–mouse IL-12
p40/p70 mAb (clone C15.6; PharMingen). Detection antibody
was biotinylated rat anti–mouse IL-12 p40/p70 (clone C17.8;
PharMingen). Streptavidin–horseradish peroxidase and ABTS
(Sigma-Aldrich) were used as enzyme and substrate, respectively.
 
Results
 
Agonistic CD40 Antibody or LPS Treatment Induces Pheno-
typic Maturation of Murine DCs.
 
To study the effect of
maturation on DC function, we used the well established
murine DC line D1 (12). D1 cells can be maintained in
culture in an immature state, as indicated by very low lev-
els of costimulatory molecules (B7.2 [CD86] and CD40)
and low to intermediate levels of MHC class I (K
 
b
 
) and II
(I-A
 
b
 
), respectively (Fig. 1). When incubated with the CD40-
specific agonistic antibody FGK45 or the CD40-indepen-
dent stimulus LPS for 48 h, D1 cells exhibit strongly ele-
vated levels of the costimulatory molecules B7.2 and CD40
as well as MHC class I and II (Fig. 1). This demonstrates
that triggering of CD40 on D1 cells using the FGK45 mAb
induced maturation of these cells similar to LPS. 
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Improved Induction of Allospecific T Cell Responses by
FGK45- and LPS-treated D1 Cells.
 
We observed that
LPS- or FGK45-matured D1 cells are more efficient in
presenting both MHC class I and class II binding peptides
derived from OVA to peptide-specific MHC class I– or
class II–restricted T cell hybridomas (data not shown). This
indicates that the induced MHC class I and class II mole-
cules are functional and that the elevated expression of
these molecules is associated with more efficient antigen
presentation. We therefore investigated whether FGK45-
or LPS-treated D1 cells are more efficient in induction of a
primary MLR. Immature D1 cells and LPS- or FGK45-
treated D1 cells were used as allogeneic stimulators for
unprimed BALB/c spleen cells. B6 spleen cells were used
as syngeneic control. D1 cells were titrated and cultured
with a fixed number of spleen cells for 4 d. Both FGK45-
and LPS-activated D1 cells induced much higher alloprolif-
eration than nontreated D1 cells (Fig. 2 A). In the same ex-
periment, we tested the presence of allospecific cytotoxic T
cells in the MLR. After 6 d, the cultured cells were tested
for specific cytotoxicity. CTL induction in vitro by both
FGK45- and LPS-activated D1 cells was much more effi-
cient than by immature D1 cells (Fig. 2 B). Thus, treatment
of D1 cells with FGK45 or LPS led to functional matura-
tion, which resulted in acquisition of the capacity to induce
strong alloproliferative and allocytotoxic T cell responses.
 
In Vivo Priming of Antigen-specific CTLs by CD40- or LPS-
stimulated D1 Cells in CD4-depleted Mice.
 
Next, we inves-
tigated whether the phenotypic and functional differences
between immature and activated D1 cells as observed in
vitro had consequences for their capacity to prime specific
CTL immunity in vivo. Immature D1 cells, exogenously
loaded with a human adenovirus CTL epitope (E1A
 
CTL
 
),
were injected into CD4-depleted mice. 10 d after immuni-
zation, spleens were harvested and splenocytes were restim-
ulated in vitro with Ad5E1-MECs. After 6 d, epitope-spe-
Figure 1. Both agonistic
CD40 antibody and LPS treat-
ment induce phenotypic matura-
tion of D1 cells. D1 cells were
treated with LPS or CD40-stim-
ulating antibody FGK45 or left
untreated (immature) for 48 h
and stained with antibodies
against the indicated markers.
Data from one representative ex-
periment out of three experi-
ments performed are shown.
Numbers indicate the median
fluorescence intensity.
Figure 2. Efficient induction of primary al-
lospecific responses in vitro by mature D1 cells.
D1 cells (H-2b), treated with agonistic CD40
antibody FGK45 or LPS for 48 h, were used as
stimulator cells in a proliferation assay with 105
BALB/c (H-2d) or control syngeneic B6 (H-2b)
responder cells (A) or as stimulator cells in bulk
cultures for the induction of allospecific CTLs
(B). For CTL induction, 104 D1 cells were in-
cubated with 3 3 106 BALB/c spleen cells for
6 d. CTL activity was measured in a cytotoxicity
assay using targets of H-2b haplotype (RMA) or
H-2d haplotype (P815). Values represent means
of triplicates from one representative experi-
ment out of three performed. 
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cific CTL activity was measured in a cytotoxicity assay.
E1A
 
CTL
 
 peptide–loaded immature D1 cells did not prime
peptide-specific CTLs in CD4-depleted mice (Figs. 3 A
and 4 C), in agreement with our recent study (15) describ-
ing the lack of Ad5E1A-specific CTL priming in the ab-
sence of CD4
 
1
 
 T cell help. However, in this study, CTL
priming was restored by in vivo CD40 triggering, which is
thought to activate bone marrow–derived APCs in vivo.
Therefore, we studied whether in vitro–activated D1 cells,
using agonistic CD40 antibody or LPS as stimuli (16), were
able to induce priming of peptide-specific CTLs in vivo. In
contrast to immature D1 cells (Fig. 3 A, top panel), D1
cells activated in vitro by FGK45 (Fig. 3 B, top panel) or
LPS (Fig. 3 C, top panel) indeed primed E1A
 
CTL
 
-specific
CTLs in vivo in CD4-depleted mice. The induction of
E1A
 
CTL
 
-specific cytotoxicity correlated with elevated num-
bers of CD8
 
1
 
 T cells in the bulk cultures that stained with
PE-conjugated H-2D
 
b
 
 tetramers containing the E1A
 
CTL
 
peptide (D
 
b
 
/E1A) (Fig. 3, bottom panel).
 
In Vivo Priming of Antigen-specific CTLs in CD4-depleted
Mice by D1 Cells Stimulated with CD4
 
1
 
 Th Cells Plus Anti-
gen.
 
The physiological activation signal through CD40 is
thought to be delivered by CD40L
 
1
 
CD4
 
1
 
 Th cells. We
therefore investigated whether in vitro incubation of D1
cells with peptide-specific Th cells resulted in functional
activation of these APCs. Phenotypic maturation (Fig. 4 A)
and IL-12 p40 production by D1 cells (Fig. 4 B) was in-
duced by incubation of D1 cells with OVA-specific Th
cells in the presence but not the absence of OVA
 
Th
 
 pep-
tide. As already shown in Fig. 3 A, immunization of CD4-
depleted mice with peptide-loaded immature D1 cells failed
to induce significant CTL immunity (Fig. 4 C). In contrast,
five out of eight mice immunized with E1A
 
CTL
 
 peptide–
loaded D1 cells that were preincubated with the OVA-spe-
cific Th cells showed strong E1A-specific CTL immunity
(Fig. 4 D). No detectable CTL activity against control
E7
 
CTL
 
 peptide–loaded target cells was observed for mice in-
Figure 3. Induction of primary peptide-specific CTL responses in vivo
by D1 cells treated with agonistic CD40 antibody or LPS. Immature D1
cells (A) and FGK45- (B) or LPS-treated (C) D1 cells were used for in
vivo CTL induction by loading them with E1ACTL peptide and injecting
them into CD4-depleted B6 mice. Three mice were injected with imma-
ture D1 cells, and four mice were injected with FGK45- or LPS-treated
D1 cells. After 10 d, 5 3 106 spleen cells were restimulated in vitro using
5 3 105 Ad5E1-MECs. After 6 d, cells were used in a cytotoxicity assay
using targets loaded with E1ACTL peptide or E7CTL peptide as control.
Data shown in the top panels are means of triplicates from one represen-
tative experiment out of three experiments performed. The bottom pan-
els show detection of E1ACTL-specific CD81 cells in bulk cultures. Bulk
cultures were analyzed for the presence of CD81 cells capable of interact-
ing with the H-2Db–E1ACTL tetrameric complexes. Indicated are per-
centages of the CD81 cells staining with H-2Db–E1ACTL tetramers.
Figure 4. Priming of peptide-specific CTLs in vivo by D1 cells stimu-
lated in vitro by specific CD41 Th cells. B7.2 (CD86) expression of D1
cells was measured after 48-h incubation with Th1 cells in the presence or
absence of 5 mM OVATh peptide (A). IL-12 p40 production was mea-
sured in supernatants of cultures containing D1 cells and OVATh-specific
Th1 cells in the presence or absence of OVATh peptide (B). Immature D1
cells (C and E) and D1 cells incubated with OVATh-specific Th1 cells and
OVATh peptide (D and F) were used for in vivo CTL induction after
loading with E1ACTL peptide and injecting them into CD4-depleted
mice. Four mice were injected with E1ACTL-loaded immature D1 cells
(C and E); eight mice were injected with E1ACTL-loaded D1 cells that
had been preincubated for 48 h with OVATh-specific Th cells in the pres-
ence of 5 mM OVATh peptide (D and F). 10 d after immunization, spleen
cells were restimulated with Ad5E1-MECs and tested in a cytotoxicity as-
say using E1ACTL peptide–loaded (C and D) or control E7CTL peptide–
loaded (E and F) RMA cells as targets. Data shown are means of tripli-
cates. Each line represents one mouse.149 Schuurhuis et al. Brief Definitive Report
jected with immature (Fig. 4 E) or Th-treated (Fig. 4 F)
D1 cells. Therefore, in vitro Th-mediated activation em-
powered the DCs to prime CTL immunity in vivo.
Discussion
These experiments provide formal evidence that CTL
priming in vivo depends on DC activation. The required
DC activation state can be induced by CD41 Th cells or by
triggering of DCs with agonistic CD40 antibody or LPS.
Although the concept that DCs require maturation for
efficient induction of T cell responses is widely recognized
(1, 2, 4, 16), it has been mainly shown for induction of
proliferative responses. In the “licence to kill” model (17,
18) supported by recent papers from three groups (9–11),
Th cells activate APCs, thereby licensing them to directly
activate CTLs. CD40-mediated maturation of mouse and
human DCs by soluble (16, 19) and transfected CD40L-
(20) or CD40-specific antibody (11) has been reported.
However, in studies where immature and mature DCs are
compared for CTL induction or tumor protection, DCs in
the “immature” state express already quite high levels of
costimulatory and MHC molecules (11, 19, 21). These
studies therefore allow no firm conclusions on the DC
phenotype required for CTL induction. Our experience
with culturing, for example, bone marrow–derived DCs in
the presence of GM-CSF is that the purity and activation
status of the resulting cells varies considerably between ex-
periments, precluding firm conclusions on correlations
between phenotype and function. By using the spleen-
derived immature DC line D1, we were able to obtain a
constant and reproducible source of pure and immature
DCs that could be induced to mature by physiological
(anti-CD40) and bacterial (LPS) stimuli in a well controlled
fashion.
The anti-CD40 antibody FGK45 was used successfully
in recent in vivo studies, illustrating the importance of the
CD40–CD40L interaction in CTL induction (9, 10). Anti-
body-induced CD40 activation even caused a therapeutic
effect of a peptide-based CTL-inducing vaccine against es-
tablished HPV16-induced mouse tumors, whereas this vac-
cine had only preventive activity in the absence of CD40
triggering (15). However, in these studies, no formal proof
was obtained that the in vivo FGK45 treatment directly
stimulated DCs and that this was causally related to the ob-
served effects. In this study, we show that the antibody
FGK45 directly activates the DC line D1, endowing these
DCs with powerful CTL-inducing capacity in vitro and in
vivo.
FGK45- and LPS-treated D1 cells showed elevated lev-
els of MHC class I and II and strongly increased levels of
the costimulatory molecules B7.2 and CD40. Incubation
with CD40L–CD8 fusion protein led to a similar level of
phenotypic maturation of D1 cells (data not shown), indi-
cating that FGK45 triggers CD40 in a physiological way.
Mature D1 cells were capable of effective induction of both
MHC class I– and class II–directed alloresponses in vitro
and peptide-specific CTL responses in vivo. The acquisi-
tion of the capacity to induce CTLs most likely is the result
of both the increase in the expression of MHC class I and
costimulatory molecules and the profile of cytokine pro-
duction by mature DCs. Our data suggest that activation of
the DCs is more important than the way in which the cells
are activated for induction of CTL responses. The effi-
ciency of CTL induction in vivo in CD4-depleted mice by
in vitro LPS-matured DCs suggests that even CD40-inde-
pendent activation of DCs leads to efficient CTL induc-
tion. This indicates the possibility that CD81 CTL re-
sponses can be induced both by CD41 Th-dependent
(CD40-mediated) and CD41 Th-independent pathways of
DC activation. CD40 ligation by CD40L expressed on
CD41 Th cells might be the most relevant maturation con-
dition for DCs in case of the lack of inflammatory condi-
tions, such as many instances of tumor growth or responses
to minor histocompatibility antigens, both of which are
profoundly CD41 Th cell dependent (22, 23). In a recent
study, CD40-independent, Th-dependent CD81 T cell
priming was reported, although a major CD40-dependent
pathway of CTL activation was shown (21). In the case of
strong inflammatory viruses or bacteria, however, DCs can
apparently become activated in a CD41 Th cell–indepen-
dent way (24–26). In addition, antiviral CD81 T cells were
shown to be capable of inducing functional maturation of
DCs in the absence of CD41 Th cells (27). Clearly, the ex-
tent of DC maturation and/or polarization is a major deter-
minant of the CD41 helper dependence of CTL responses
against infectious agents and tumor cells.
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